Effect of esketamine on serum neurotransmitters in patients with postpartum depression: a randomized controlled trial
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The development of postpartum depression has been linked to fluctuations in the levels of neurotransmitters in the human body, such as 5-hydroxytryptamine (5-HT), dopamine (DA), noradrenaline (Norepinephrine, NE), and brain derived neurotrophic factor (BDNF). Research has indicated that the antidepressant effect of esketamine are mediated by monoamine transmitters and neurotrophic factors. Therefore, we postulate that intravenous administration of esketamine in patients with postpartum depression may alter the serum concentrations of these neurotransmitters. METHODS: Three hundred fifteen patients with postpartum depression were selected and divided into two groups based on randomized numerical expression: esketamine (E) group (0. 25 mg/kg esketamine) and control (C) group (a same volume of 0.9% saline), all the drugs were pumped for 40 min. After the end of drug pumping, all patients were continuously observed for 2 h. Changes in serum levels of 5-HT, DA, NE, BDNF were recorded before drug administration and on the 3rd day after drug administration. The scores of Edinburgh Postnatal Depression Scale (EPDS) were calculated before drug administration, and on the 3rd day and on the 30th day after drug administration. Dizziness, headache, nausea, vomiting, drowsiness, and feeling of detachment occurred were recorded within 2 h after drug administration. RESULTS: Before drug administration, the serum concentrations of 5-HT,DA,BDNF,NE in Group E and Group C were namely (0. 91 ± 0. 19 vs. 0. 98 ± 0. 21, P = 0. 181), (2. 38 ± 0. 35 vs. 2. 32 ± 0. 32, P = 0. 491), (3. 07 ± 0. 89 vs 3. 02 ± 0. 88, P = 0. 828), (39. 79 ± 7. 78 vs 41. 34 ± 10. 03, P = 0. 506). On the third day post-medication, the serum concentrations of 5-HT,DA,BDNF,NE in Group E and Group C were namely (1. 42 ± 0. 35 vs. 0. 96 ± 0. 24, P < 0. 001), (3. 99 ± 0. 17 vs. 2. 41 ± 0. 28, P < 0. 001),(5. 45 ± 0. 81 vs 3. 22 ± 0. 76, P < 0. 001),(44. 36 ± 9. 98 vs 40. 69 ± 11. 75, P = 0. 198). Before medication, the EPDS scores were (16. 15 ± 3. 02 vs 17. 85 ± 3. 89, P = 0. 064). on the third day after medication, the Group E had significantly reduced scores (12. 98 ± 2. 39 vs 16. 73 ± 3. 52, P < 0. 001). On the 30rd day after medication, EPDS scores between the two groups were (16. 34 ± 3. 43 vs 16. 91 ± 4. 02, p = 0. 203). Within 2 h of medication, the rate of adverse events was similar between the two groups. CONCLUSIONS: Small doses of esketamine can increase the serum concentration of 5-HT,DA,BDNF, and in the short term, decrease EPDS scores, and improve postpartum depressive symptoms. TRIAL REGISTRATION: Retrospectively registered in the Chinese Clinical Trial Registry (ChiCTR2300078343, 2023/12/05).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“one study reported that intravenous esketamine at a dose of 0.25 mg/kg significantly increased plasma BDNF levels in patients with postpartum depression, with this increase measured three days after infusion [104].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [104]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For esketamine, studies have been conducted in special populations, such as patients with postpartum depression [104] or those who have undergone surgery [99,105].”
From Variations in BDNF and Their Role in the Neurotrophic Antidepressant Mechanisms of Ketamine and Esketamine: A Review (2024) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of perinatal mental disorders on the fetus and child
Stein, A., Pearson, R. M., Goodman, S. H., Rapa, E., Rahman, A., McCallum, M., Howard, L. M., & Pariante, C. M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61277-0 · Cited by 2,166 · cited 1×
“" Research has shown that maternal postpartum depression can contribute to cognitive and behavioral issues in infants, posing significant challenges to families and society [14, 15].”
BackgroundKetamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260 · cited 3×
“…NMDA receptors on γ-aminobutyric acid (GABA) interneurons and activating α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (α-amino- 3-hydroxy-5-methyl-4-isoxazole-propionicacid (AMPA) receptor, which increases with BNDF levels, a neurotrophic signal that restores synaptic function [7, 8].”
BackgroundMcIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731 · cited 1×
“A study by Roger S et al. [27] suggested a dose of 0.”
Singh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466
Pathophysiological mechanisms implicated in postpartum depression
Payne, J. L., & Maguire, J. (2019) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2018.12.001 · Cited by 459 · cited 1×
“The etiology of PPD is multifaceted, with most researchers postulating that it is caused by a collection of psychological, physiological, social and environmental factors [4, 5].”
BackgroundFava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433 · cited 1×
“However, it has been shown that [25, 26] that intravenous esketamine is acceptable in the range of 0.”
BackgroundKetamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385 · cited 1×
“Esketamine has been reported to have several adverse effects including dizziness, somnolence, nausea, vomiting, and a feeling of dissociation, while less common adverse effects include dyspepsia, dyspnoea, drug intolerance, increased blood pressure, and increased heart rate [29, 30].”
BackgroundWajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308 · cited 1×
“Additionally, literature reports that repeated administration of ketamine nasal spray can rapidly treat refractory depression in the short term, and its antidepressant effects persist for several weeks after discontinuation of treatment [32].”
BackgroundHare, B. D., Shinohara, R., Liu, R. J., Pothula, S., DiLeone, R. J., & Duman, R. S. (2019) · Nature Communications · doi:10.1038/s41467-018-08168-9 · Cited by 217
Naoi, M., Maruyama, W., & Shamoto-Nagai, M. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1709-8 · Cited by 173
Oxytocin and postpartum depression: A systematic review
Thul, T. A., Corwin, E. J., Carlson, N. S., Brennan, P. A., & Young, L. J. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104793 · Cited by 139 · cited 2×
“Recent studies have demonstrated that PPD is closely related to abnormal changes in neurotransmitter levels, including the decline of serum neurotransmitters, such as 5-hydroxy-tryptamine (5-HT), dopamine (DA), norepinephrine (NE) [5, 6].”
BackgroundPham, T. H., Mendez-David, I., Defaix, C., Guiard, B. P., Tritschler, L., David, D. J., & Gardier, A. M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.010 · Cited by 136
Suicides during pregnancy and 1 year postpartum in Sweden, 1980–2007
Esscher, A., Essén, B., Innala, E., Papadopoulos, F. C., Skalkidou, A., Sundström-Poromaa, I., & Högberg, U. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.114.161711 · Cited by 134 · cited 1×
“" Research has shown that maternal postpartum depression can contribute to cognitive and behavioral issues in infants, posing significant challenges to families and society [14, 15].”
BackgroundPain, not chronic disease, is associated with the recurrence of depressive and anxiety disorders
Gerrits, M. M., van Oppen, P., Leone, S. S., van Marwijk, H. W., van der Horst, H. E., & Penninx, B. W. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-187 · Cited by 106 · cited 2×
“Cavalleri L et al. [18] found that ketamine and its enantiomer s-keta-mine improved the mood of the patients by modulating the mesolimbic dopamine system (D2 and D3 receptors) and monoamine transporters.”
BackgroundEffect of Pretreatment of S-Ketamine On Postoperative Depression for Breast Cancer Patients
Liu, P., Li, P., Li, Q., Yan, H., Shi, X., Liu, C., Zhang, Y., & Peng, S. (2021) · Journal of Investigative Surgery · doi:10.1080/08941939.2019.1710626 · Cited by 103 · cited 1×
“This activation leads promotes the production of BDNF. Liu et al. found that serum BDNF levels were elevated in breast cancer patients with mild to moderate depression treated with esketamine [24].”
BackgroundTHERAPEUTIC MECHANISMS OF KETAMINE
Mihaljević, S., Pavlović, M., Reine, K., & Čačić, M. (2020) · Psychiatria Danubina · doi:10.24869/psyd.2020.325 · Cited by 95
Ago, Y., Tanabe, W., Higuchi, M., Tsukada, S., Tanaka, T., Yamaguchi, T., Igarashi, H., Yokoyama, R., Seiriki, K., Kasai, A., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz041 · Cited by 92 · cited 1×
“Another important pathway mediating the antidepressant effects of esketamine is the activation of monoam-inergic receptors and increased release of monoamine transmitters such as 5-HT and DA [8, 9].”
BackgroundRoomruangwong, C., Withayavanitchai, S., & Maes, M. (2016) · Sexual & Reproductive Healthcare · doi:10.1016/j.srhc.2016.03.001 · Cited by 47
Ketamine sensitization: Influence of dose, environment, social isolation and treatment interval
Trujillo, K. A., & Heller, C. Y. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112271 · Cited by 40 · cited 1×
“Esketamine has been reported to have several adverse effects including dizziness, somnolence, nausea, vomiting, and a feeling of dissociation, while less common adverse effects include dyspepsia, dyspnoea, drug intolerance, increased blood pressure, and increased heart rate [29, 30].”
BackgroundMechanisms of Action of Ketamine and Esketamine
Schatzberg, A. F. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21060653 · Cited by 30 · cited 1×
“This action enhances neurotrophic signaling pathways, promoting the restoration of synaptic function [20].”
BackgroundUrothelial toxicity of esketamine in the treatment of depression
Findeis, H., Sauer, C., Cleare, A. J., Bauer, M., & Ritter, P. S. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05611-y · Cited by 29
Plasma level of brain-derived neurotrophic factor (BDNF) in patients with postpartum depression
Lee, Y.-J., Kim, K. H., Lee, B.-H., & Kim, Y. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110245 · Cited by 24 · cited 3×
“…NMDA receptors on γ-aminobutyric acid (GABA) interneurons and activating α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (α-amino- 3-hydroxy-5-methyl-4-isoxazole-propionicacid (AMPA) receptor, which increases with BNDF levels, a neurotrophic signal that restores synaptic function [7, 8].”
BackgroundWojdacz, R., Święcicki, Ł., & Antosik-Wójcińska, A. Z. (2017) · Psychiatria Polska · doi:10.12740/pp/75635 · Cited by 21 · cited 1×
“A single intravenous sub-clinical dose of ketamine produces a strong antidepressant effect that peaks within 72 h and is maintained for approximately 1 week [13].”
BackgroundSoffer, M. D., Adams, Z. M., Chen, Y. S., & Fox, N. S. (2018) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2018.1484096 · Cited by 17 · cited 1×
“This condition is also aggravated by diseases and can lead to hallucinations [1].”
Background
Research works printed but not linked: 8
- 2. Liu D, Ma Y, Yu G, Kuang J. Meta analysis of the detection rate of postpartum depression in China. Chinese Journal of Evidence Based Medicine. 2019;19(12):1409–15.
- 3. Li L, An X, Zhang J, Huang L, Zhang X. Meta analysis of the detection rate of postpartum depression in elderly mothers in China. Chinese Journal of General Medicine. 2024;27(11):1363–9.
- 10. Gu P, Jiang X, Du B, Yao L, Song J. The effect of s-ketamine PCIA on postpartum depression in pregnant women undergoing cesarean section. Chinese Journal of Anesthesiology. 2021;41(3):274–7.
- 11. Liu Y, Li X. The effect of s-ketamine combined with hydromorphone on postoperative analgesia and postpartum depression after cesarean section. Shandong Medical Journal. 2021;61(19):84–7.
- 23. Zhou Y, Wang S, Yang M, Huang Z, Ma J, Duan K. Analysis of the correlation between BDNF gene polymorphism and postpartum depression in cesarean section women. Chinese Journal of Medicine. 2017;42(6):538–44.
- 26. Schwartz J, Murrough JW, Iosifescu DV. Short term ketamine administration for refractory depression: focusing on cardiovascular safety. Psychiatry Danub. 2019;31(Supplementary 3):585–90.
- 28. Shang Y, Li S, Zheng Q, et al. Study on the effect of different doses of intravenous ketamine on postoperative depression in cesarean section women. Chinese Maternal and Child Health Research. 2023;34(9):28–34.
- 31. Dandan L, Xiao H, Changwei W, et al. Meta-analysis of the effects of perioperative ketamine application on postpartum depression in cesarean section mothers. Journal of Clinical Anesthesiology. 2021;37(05):506–10.
Cited by
Pardossi, S., Fagiolini, A., & Cuomo, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313098 · Cited by 51
“…treated with esketamine are mostly from studies of specific populations (Table 2): one study reported that intravenous esketamine at a dose of 0.25 mg/kg significantly increased plasma BDNF levels in patients with postpartum depression, with this increase measured three days after infusion [104].”
InfluentialAntos, Z., Żukow, X., Bursztynowicz, L., & Jakubów, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413658 · Cited by 21
“The dose used in this study was 0.25 mg/kg of esketamine, and serum BDNF levels were compared between pre-administration and the third-day post-administration [131].”
InfluentialHuang, C., Hu, L., Wu, L., Geng, F., Wong, G. T. C., Zhang, Y., Reif, A., Bao, Y., Xue, Q., & Lü, L. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03320-6 · Cited by 17
Progress in the Application of Esketamine During the Perioperative Period
Wang, J., Hu, Q., Cao, R.-Y., Liu, W.-K., Guo, M., Lin, Y., Zhong, M., Liang, W., & Wang, L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s579462 · Cited by 8
“43 46 Although the overall incidence of adverse psychiatric events associated with esketamine is relatively high, most symptoms are transient and typically do not require pharmacologic intervention in clinical practice.”
Self-citationZhang, Y., Li, S., Wu, C., Song, L., Hu, L., & Lu, J. G. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s502718 · Cited by 5
“27 The change of emotion after operation can significantly impact the rapid recovery speed of patients.”
Metadata
- Authors
- Jiang, Q., Qi, Y., Zhou, M., Dong, Y., Zheng, W., Zhu, L., Li, Y., Zhou, H., & Wang, L.
- Affiliations
- Xuzhou Medical College (CN)
- Corresponding author
- Wang, Liwei
- Venue
- BMC Anesthesiology
- Published
- 2024-08-19
- Volume
- 24
- Issue
- 1
- Pages
- 293-293
- ISSN
- 1471-2253 (ISSN-L)
- PMC
- PMC11331807
- OpenAlex
- W4401709616
- Cited by
- 14
- References
- 24
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 2
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- BMC Anesthesiology (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Government of Jiangsu Province
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- esketamine, postpartum depression, serotonin, dopamine, norepinephrine, brain-derived neurotrophic factor, monoamines, antidepressant effects, adverse effects, Edinburgh Postnatal Depression Scale, maternal mental health, NMDA receptor antagonists, ketamine derivatives, neurotrophic factors, depression biomarkers, treatment-resistant depression
- MeSH terms
- Adult, Antidepressive Agents, Dopamine, Female, Humans, Ketamine, Norepinephrine, Serotonin, Neurotransmitter Agents, Depression, Postpartum, Brain-Derived Neurotrophic Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.